University of Hertfordshire

From the same journal

From the same journal

By the same authors

Standard

Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. / Pan, Yi; Norton, Sam; Gwinnutt, James M.; Kearsley-Fleet, Lianne; Symmons, Deborah P.M.; Lunt, Mark; Young, Adam; Hyrich, Kimme L.; Verstappen, Suzanne M.M.

In: PLoS ONE, Vol. 14, No. 5, e0215999, 20.05.2019.

Research output: Contribution to journalArticle

Harvard

Pan, Y, Norton, S, Gwinnutt, JM, Kearsley-Fleet, L, Symmons, DPM, Lunt, M, Young, A, Hyrich, KL & Verstappen, SMM 2019, 'Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity', PLoS ONE, vol. 14, no. 5, e0215999. https://doi.org/10.1371/journal.pone.0215999

APA

Pan, Y., Norton, S., Gwinnutt, J. M., Kearsley-Fleet, L., Symmons, D. P. M., Lunt, M., ... Verstappen, S. M. M. (2019). Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. PLoS ONE, 14(5), [e0215999]. https://doi.org/10.1371/journal.pone.0215999

Vancouver

Author

Pan, Yi ; Norton, Sam ; Gwinnutt, James M. ; Kearsley-Fleet, Lianne ; Symmons, Deborah P.M. ; Lunt, Mark ; Young, Adam ; Hyrich, Kimme L. ; Verstappen, Suzanne M.M. / Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. In: PLoS ONE. 2019 ; Vol. 14, No. 5.

Bibtex

@article{9ba21a8cb3db4b27916daadd6f00495e,
title = "Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity",
abstract = "BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease Activity Score [DAS28] >5.1) and have failed ≥2 previous conventional synthetic DMARDs (csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet often have poor outcomes. This study aimed to identify trajectory groups of disability scores over three years in RA patients with MDA.METHODS: The study included biologic-na{\"i}ve patients receiving csDMARDs only with MDA (3.2 <DAS28≤ 5.1) when recruited to the control cohort of the British Society for Rheumatology Biologics Register-RA (BSRBR-RA). Disability scores, measured using the Health Assessment Questionnaire (HAQ), were recorded every six months for three years. Trajectories of HAQ scores over follow-up were assessed using latent class growth models (LCGMs). Baseline age, gender, DAS28, symptom duration, rheumatoid factor status, number of prior csDMARDs and co-morbidities were assessed as potential predictors of group membership.RESULTS: In total, 1274 patients were included (mean age: 61 years (standard deviation: 12), 71.4{\%} women). The best fitting model included seven HAQ trajectories. These trajectories were horizontal over follow-up and were related to baseline HAQ: very-low (6.8{\%}, baseline (BL) HAQ: 0.22), low (11.5{\%}, BL HAQ: 0.41), low-moderate (17.0{\%}, BL HAQ: 0.93), moderate (13.4{\%}, BL HAQ: 1.09), high-moderate (19.5{\%}, BL HAQ: 1.61), severe (23.2{\%}, BL HAQ: 1.98) and very-severe (8.6{\%}, BL HAQ: 2.54). Higher DAS28, older age, female gender, longer disease duration and more co-morbidities were independently associated with higher HAQ trajectory group.CONCLUSION: There is substantial heterogeneity in baseline HAQ scores in this population, and the trajectories of HAQ scores after baseline are, on average, relatively flat. As bDMARD therapy has been shown to improve HAQ scores, patients with MDA but high HAQ scores may benefit from a more aggressive approach to therapy.",
author = "Yi Pan and Sam Norton and Gwinnutt, {James M.} and Lianne Kearsley-Fleet and Symmons, {Deborah P.M.} and Mark Lunt and Adam Young and Hyrich, {Kimme L.} and Verstappen, {Suzanne M.M.}",
year = "2019",
month = "5",
day = "20",
doi = "10.1371/journal.pone.0215999",
language = "English",
volume = "14",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity

AU - Pan, Yi

AU - Norton, Sam

AU - Gwinnutt, James M.

AU - Kearsley-Fleet, Lianne

AU - Symmons, Deborah P.M.

AU - Lunt, Mark

AU - Young, Adam

AU - Hyrich, Kimme L.

AU - Verstappen, Suzanne M.M.

PY - 2019/5/20

Y1 - 2019/5/20

N2 - BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease Activity Score [DAS28] >5.1) and have failed ≥2 previous conventional synthetic DMARDs (csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet often have poor outcomes. This study aimed to identify trajectory groups of disability scores over three years in RA patients with MDA.METHODS: The study included biologic-naïve patients receiving csDMARDs only with MDA (3.2 <DAS28≤ 5.1) when recruited to the control cohort of the British Society for Rheumatology Biologics Register-RA (BSRBR-RA). Disability scores, measured using the Health Assessment Questionnaire (HAQ), were recorded every six months for three years. Trajectories of HAQ scores over follow-up were assessed using latent class growth models (LCGMs). Baseline age, gender, DAS28, symptom duration, rheumatoid factor status, number of prior csDMARDs and co-morbidities were assessed as potential predictors of group membership.RESULTS: In total, 1274 patients were included (mean age: 61 years (standard deviation: 12), 71.4% women). The best fitting model included seven HAQ trajectories. These trajectories were horizontal over follow-up and were related to baseline HAQ: very-low (6.8%, baseline (BL) HAQ: 0.22), low (11.5%, BL HAQ: 0.41), low-moderate (17.0%, BL HAQ: 0.93), moderate (13.4%, BL HAQ: 1.09), high-moderate (19.5%, BL HAQ: 1.61), severe (23.2%, BL HAQ: 1.98) and very-severe (8.6%, BL HAQ: 2.54). Higher DAS28, older age, female gender, longer disease duration and more co-morbidities were independently associated with higher HAQ trajectory group.CONCLUSION: There is substantial heterogeneity in baseline HAQ scores in this population, and the trajectories of HAQ scores after baseline are, on average, relatively flat. As bDMARD therapy has been shown to improve HAQ scores, patients with MDA but high HAQ scores may benefit from a more aggressive approach to therapy.

AB - BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease Activity Score [DAS28] >5.1) and have failed ≥2 previous conventional synthetic DMARDs (csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet often have poor outcomes. This study aimed to identify trajectory groups of disability scores over three years in RA patients with MDA.METHODS: The study included biologic-naïve patients receiving csDMARDs only with MDA (3.2 <DAS28≤ 5.1) when recruited to the control cohort of the British Society for Rheumatology Biologics Register-RA (BSRBR-RA). Disability scores, measured using the Health Assessment Questionnaire (HAQ), were recorded every six months for three years. Trajectories of HAQ scores over follow-up were assessed using latent class growth models (LCGMs). Baseline age, gender, DAS28, symptom duration, rheumatoid factor status, number of prior csDMARDs and co-morbidities were assessed as potential predictors of group membership.RESULTS: In total, 1274 patients were included (mean age: 61 years (standard deviation: 12), 71.4% women). The best fitting model included seven HAQ trajectories. These trajectories were horizontal over follow-up and were related to baseline HAQ: very-low (6.8%, baseline (BL) HAQ: 0.22), low (11.5%, BL HAQ: 0.41), low-moderate (17.0%, BL HAQ: 0.93), moderate (13.4%, BL HAQ: 1.09), high-moderate (19.5%, BL HAQ: 1.61), severe (23.2%, BL HAQ: 1.98) and very-severe (8.6%, BL HAQ: 2.54). Higher DAS28, older age, female gender, longer disease duration and more co-morbidities were independently associated with higher HAQ trajectory group.CONCLUSION: There is substantial heterogeneity in baseline HAQ scores in this population, and the trajectories of HAQ scores after baseline are, on average, relatively flat. As bDMARD therapy has been shown to improve HAQ scores, patients with MDA but high HAQ scores may benefit from a more aggressive approach to therapy.

UR - http://www.scopus.com/inward/record.url?scp=85066069542&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0215999

DO - 10.1371/journal.pone.0215999

M3 - Article

VL - 14

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 5

M1 - e0215999

ER -